HAE Relative Valuation
HAE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HAE is overvalued; if below, it's undervalued.
Historical Valuation
Haemonetics Corp (HAE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.30 is considered Undervalued compared with the five-year average of 23.39. The fair price of Haemonetics Corp (HAE) is between 96.44 to 157.39 according to relative valuation methord. Compared to the current price of 74.41 USD , Haemonetics Corp is Undervalued By 22.84%.
Relative Value
Fair Zone
96.44-157.39
Current Price：74.41
22.84%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
4.37
P/B
Median3y
4.73
Median5y
5.12
3.97
FCF Yield
Median3y
2.93
Median5y
2.55
Competitors Valuation Multiple
The average P/S ratio for HAE's competitors is 3.66, providing a benchmark for relative valuation. Haemonetics Corp Corp (HAE) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -3.70%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Haemonetics Corp (HAE) currently overvalued or undervalued?
What is Haemonetics Corp (HAE) fair value?
How does HAE's valuation metrics compare to the industry average?
What is the current P/B ratio for Haemonetics Corp (HAE) as of Jul 17 2025?
What is the current FCF Yield for Haemonetics Corp (HAE) as of Jul 17 2025?
What is the current Forward P/E ratio for Haemonetics Corp (HAE) as of Jul 17 2025?